RESOURCES

whitepaper

Nov 30, 2018

The phosphatidylinositol 3-kinase (PI3K)/serine-threonine protein kinase Akt is a vital signaling cascade involved in cell survival, progression and thus causes various types of cancers. Various kinase inhibitors targeting PI3K/Akt have been extensiv...

whitepaper

Nov 30, 2018

Gene therapy, the modification of genetic information in living cells to address a mutated gene, has the ability to dramatically change the way diseases are treated, or even cured. First conceptualized in the early 1970s, the seminal paper on the sub...

whitepaper

Nov 25, 2018

Alzheimer’s disease (AD) is one of the most common multifactorial diseases, including a range of abnormal cellular/molecular processes occurring in different regions of the brain. This disease is considered to be a major contributor to dementia...

whitepaper

Nov 22, 2018

The briefing note at hand has been prepared to annotate with further conceptual clarity the structure and organization of the Framework for Action, with the objective of specifying the following: its strategic vision according to the determinants of ...

whitepaper

Nov 17, 2018

Less than a hundred years ago diabetes was a death warrant. The discovery of insulin in The 1920s was a major breakthrough. Since then, thanks to the dedicated work of scientists, researchers, doctors, and nurses in this country and abroad, there hav...

whitepaper

Nov 13, 2018

In this study, the Toxtyper is used for drug screening in drug consumption rooms which are seen as an important element to minimize drug-related health problems (e.g. infection risk) and promote contact of drug users with employees of drug help progr...

whitepaper

Nov 13, 2018

How advances in imaging technology and the use of artificial intelligence and analytics are improving the accuracy and cost of medical imaging for early cancer diagnosis, and increasing confidence in vital preventive screening programs.

whitepaper

Nov 12, 2018

Technology for People shows the way to an exciting future where healthcare technology is designed by humans, for humans, to create positive change that can transform healthcare organizations and society. Digital breakthroughs are enabling health...

whitepaper

Nov 12, 2018

Data protection regulations define how an individual’s personal information can be used by organizations, businesses, and government. These regulations also contain safeguards that seek to ensure healthcare data is not susceptible to attack, mi...

whitepaper

Nov 12, 2018

Immortality has long been treated as a work of fiction - a trait only possessed by mythological Gods and divine creatures. Is there an afterlife or life after death? Each religion or system of belief had its own way to deal with such questions. Certa...

whitepaper

Nov 10, 2018

Pharmaceuticals play a prominent role worldwide. This widespread presence is met with regulatory requirements at each phase of pharmaceutical development and manufacturing—from inspection of raw materials to quality control of final products. C...

whitepaper

Nov 10, 2018

What matters most when building and sustaining a healthcare organization? What are the precise levers to pull to promote physician well being, financial success, and better outcomes at lower cost? To answer these questions, Athena health launched an ...

whitepaper

Nov 08, 2018

The landscape of clinical trials continues to evolve over time as scientific breakthroughs and technological innovations emerge, which continue to be tracked by assessing recently initiated trials through Trialtrove’s annual Clinical Trials Rou...

whitepaper

Nov 07, 2018

Robust safety and tolerability data are essential in cancer therapeutic studies, and some trials are specifically designed with a key objective of demonstrating improved safety and tolerability. The development of a clinical trial framework and data ...

whitepaper

Nov 05, 2018

This white paper represents a key piece of research into the potential benefits of mobile working in healthcare and considers the obstacles that will have to be surmounted along the way. Given our research was conducted in the aftermath of last May&r...

whitepaper

Nov 05, 2018

Depression affects approximately 1 in 6 Americans, with 10 – 30% of depression patients becoming treatment-resistant. Find out what the pipeline looks like for depression and what the emerging strategies in this area are in Depression: New Insi...

whitepaper

Nov 02, 2018

As the pharmaceutical industry continues to look for new and innovative ways to treat disease, some companies are putting more focus on how to prevent them. Vaccine development, while a long and complex process, has the potential to save millions of ...

whitepaper

Nov 02, 2018

Mobile value chain revenues in the US grew 10 percent per annum from 2009 to 2014, and profits rose by as much as 15 percent. The year 2015 is expected to see 3 percent growth in revenues and 6 percent growth in profits.

whitepaper

Nov 02, 2018

The Center for Connected Health Policy’s (CCHP) Fall 2018 release of its report on “State Telehealth Laws and Reimbursement Policies” offers policymakers, health advocates, and other interested health care professionals a freshly re...

whitepaper

Nov 02, 2018

A Nutanix enterprise cloud reduces the cost and complexity of IT infrastructure for healthcare while improving scaling, availability, and data protection. Conventional infrastructure is no longer able to address healthcare challenges, such as regulat...

whitepaper

Oct 22, 2018

This white paper explores a number of ways that today’s modern, laboratory-based  PXRD instrumentation and advanced software can greatly assist pharmaceutical scientists in their quest to develop high quality, stable products and accelerat...

whitepaper

Oct 19, 2018

Facing increasing margin pressures—and having already implemented many proven cost reduction and revenue-increasing measures—hospitals and health systems have to find new ways of reducing their costs without compromising quality or patien...

whitepaper

Oct 18, 2018

As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 tria...

whitepaper

Oct 15, 2018

This white paper outlines the main benefits of using hard radiation for material analysis studies. X-ray powder diffractometers are generally equipped with X-ray sources using Cu anodes. For specific applications, however, switching to shorter wavele...

whitepaper

Oct 12, 2018

There are many different requirements with which in vitro diagnostic manufacturers must comply in order to place the product on the market. At the core of most of these requirements is a fundamental need to have a good quality management system (QMS)...

whitepaper

Oct 03, 2018

In the end, you need to be rewarding your sales reps with more than just money if you want to keep them motivated and if you want your sales compensation plan to deliver on its promises.

whitepaper

Oct 03, 2018

The first CRM launch truly changed the way sales were managed. We went from tracking customers on spreadsheets (and even in rolodexes) to tracking them and their attendant opportunities with software. It wasn’t long before reps started to feel ...

whitepaper

Oct 03, 2018

Let’s explore some of the current processes around pipeline management and forecasting and how they can be improved.

whitepaper

Sep 28, 2018

Countless studies and articles have confirmed that connected medical devices from implantable products like pacemakers to diagnostic devices such as CT scanners and more are indeed vulnerable to malicious exploitation. This paper offers both technica...

whitepaper

Sep 26, 2018

High-throughput sequencing technologies have revolutionized the field of human genetics, allowing researchers to more easily investigate and understand biological processes and their impact. Using these technologies, researchers can analyze entire ge...

whitepaper

Sep 21, 2018

While the outlook for medical device companies appears positive, unsustainable health care costs and new competitive forces threaten to alter the future industry landscape. If today’s manufacturers fail to stake their claim in the evolving valu...

whitepaper

Sep 19, 2018

CIO’s and IT professionals in healthcare organizations are tasked with achieving a balance between the demand for universal access to information and the need to ensure security. In particular, four critical challenges these organizations face ...

whitepaper

Sep 16, 2018

To promote sustainable development, the smart city implies a global vision that merges artificial intelligence, big data, decision making, information and communication technology (ICT), and the internet-of-things (IoT). The aging issue is an aspect ...

whitepaper

Sep 15, 2018

The publication of the stable text of the European Union (EU) Medical Devices Regulation (MDR), and the In Vitro Diagnostic Medical Devices Regulation (IVDR), in June 2016 documented political agreement between the three EU Institutions – the C...

whitepaper

Sep 10, 2018

With over 10 million new cases worldwide each year and approximately 1.7 million deaths, tuberculosis (TB) is one of the leading global threats to human health. While disease detection and control methods have yielded a steady decline in the number o...

whitepaper

Sep 06, 2018

When discussing the success of a drug therapy, a common topic amongst biopharmaceutical companies is data quality and data integrity; what the challenges are and what the key elements are to ensuring that the latest discovery is patentable, does not ...

whitepaper

Aug 27, 2018

Pervading every facet of daily life, the information superhighway that society has come to know and love – and occasionally loathe – has enabled a level of communication, collaboration, insight, and analysis that has rendered the current ...

whitepaper

Aug 24, 2018

Liquid chromatography is a technique of key importance for many areas of chemical analysis and one that has evolved with the progression of technology and instrumentation over time. Here we highlight some of the key similarities and differences betwe...

whitepaper

Aug 22, 2018

Fifty-one percent of national survey respondents say they’ve had a contact center strategy in place 3 – 5 years, and 48 percent call their strategy an enterprise transformation initiative. Can maximizing this resource take your hospital i...

whitepaper

Aug 18, 2018

The healthcare industry has never been more focused on data its promise and its pitfalls as it is today. From slashing health care spending to detecting fraud or coordinating care across multiple providers improved the use of healthcare data has been...

whitepaper

Aug 12, 2018

Cloud computing is having a profound impact on healthcare. The healthcare cloud computing market is projected to almost triple between 2015 and 2020 to $9.48 billion.1 In the same time period, the Internet of Things (IoT) the number of devices connec...

whitepaper

Aug 11, 2018

This white paper explores a number of ways that today’s modern, laboratory-based  PXRD instrumentation and advanced software can greatly assist pharmaceutical scientists in their quest to develop high quality, stable products and accelerat...

whitepaper

Aug 10, 2018

Want to improve the reliability of your neuronal cell culture experiments by increasing the survival of the neurons? This white paper shows how the B-27 Plus Neuronal Culture System increases neuron survival and improves maturation and neural network...

whitepaper

Aug 08, 2018

The koala, the only extant species of the marsupial family Phascolarctidae, is classified as ‘vulnerable’ due to habitat loss and widespread disease. We sequenced the koala genome, producing a complete and contiguous marsupial reference g...

whitepaper

Aug 08, 2018

Transitional care encompasses a broad range of services and environments designed to promote the safe and timely passage of patients between levels of health care, across care settings, and among various providers. Care settings can include a range o...

whitepaper

Aug 08, 2018

DNAtix intends to create a future ecosystem for Genetics where consumers, researchers, laboratories, and clinics operate making Genetics more accessible, transparent and anonymous. DNAtix intends to offer cutting-edge Genetics and Blockchain services...

whitepaper

Aug 03, 2018

The aim of this white paper is to demonstrate how GE Healthcare Life Sciences single-use products can be applied in the field of vaccine manufacturing. The white paper includes a brief discussion on modern vaccine processes, followed by a case study ...

whitepaper

Jul 23, 2018

Custom ICM solutions are built for you, not auditors, so they typically don’t offer visibility into actions performed over time. Auditors may lack confidence in your homegrown system, especially if they find errors or omissions. In fact, audit ...

whitepaper

Jul 23, 2018

It all ties together. You want your sales reps to behave a certain way and close a certain amount of deals in specific verticals that match your company’s 3- and/or 5-year vision, but the systems you currently have in place to drive this behavi...

whitepaper

Jul 23, 2018

You’ve reached a certain point in the evolution of your company and you know it’s time to invest in a CPQ system. But buyer beware: There’s a certain misconception around CPQ systems as being plug-in devices or turnkey-ready overlay...

whitepaper

Jul 23, 2018

The spreadsheet conundrum... Joe Smith, sales director for Great Start-Up Number 5 Billion and Thirty-One, puts on a blindfold and reaches out blindly for something, ANYTHING, to help him organize his team’s deals and commissions. He’s ho...

whitepaper

Jul 17, 2018

Quickly and easily quantitate immune checkpoint markers using a fraction of the sample volume required by traditional ELISA. In this technical note, we show how AlphaLISA can be used to detect and quantify additional immune checkpoint molecules withi...

whitepaper

Jul 14, 2018

The publication of the stable text of the European Union (EU) Medical Devices Regulation, and the In Vitro Diagnostic Medical Devices Regulation in June 2016 documents the political agreement between the three EU Institutions – the Commission, ...

whitepaper

Jul 11, 2018

This whitepaper explains how you can find ways to optimize the holistic preclinical development process. When it comes to informatics and data management, each preclinical domain is characterized by specific requirements due to their diverse scientif...

whitepaper

Jul 07, 2018

Technological advancements occur with such frequency that it’s challenging to stay on top — or ahead — of the Next Big Thing, but successful businesses need to focus attention on advancements that make internal processes easier and ...

whitepaper

Jul 07, 2018

For the 14th year in a row, AHRQ is reporting on health care quality and disparities. The annual National Healthcare Quality and Disparities Report (QDR) is mandated by Congress to provide a comprehensive overview of the quality of health care receiv...

whitepaper

Jul 06, 2018

See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Findings include. Anticipated growth and variety of data sources used by C...

whitepaper

Jul 05, 2018

As the cloud becomes more prevalent, healthcare leaders are finding themselves in a multi-cloud environment, moving beyond basic infrastructure on demand to strategic innovations such as running real-time data analytics for the management of chronic ...

whitepaper

Jun 29, 2018

More Americans are concerned about health care costs (85%) that are concerned about other common worries like retirement (73%), housing (66%), and child care (49%).1 While Republicans, Democrats, and independents are divided over many healthcare issu...

whitepaper

Jun 26, 2018

Bridging the gap from discovery to verification and validation requires high-performing instruments and software as well as competency in mass spec-based biomarker discovery and method development for biomarker verification. The Thermo Scientific&tra...

whitepaper

Jun 23, 2018

Unauthorized diversion and falsification of drug products create safety risks in the supply chain, creating life-threatening risk for patients and reducing revenue, profitability and brand equity for drug owners. To reduce the proliferation of c...

whitepaper

Jun 15, 2018

The following situation is typical for many production plants: After a routine quality check, the production process is stopped or an already produced batch is suspended because the analysis results were not within the relevant critical values. But d...

whitepaper

Jun 15, 2018

The views expressed by authors or editors do not necessarily represent the decisions or the stated policies of the European Observatory on Health Systems and Policies or any of its partners. The designations employed and the presentation of the mater...

whitepaper

Jun 12, 2018

From passive consumer to active participant, the role of the patient is changing as dramatically as the healthcare system itself. The fee-for-service, volume-based care of the past is giving way to a value-based care system focusing on quality and ou...

whitepaper

Jun 10, 2018

Pharmaceutical or biotechnology companies looking to outsource their API production are planning for success by looking at the entire development cycle. The growing desire to select one API partner to work with throughout the drug development process...

whitepaper

Jun 06, 2018

The World Health Statistics series is WHO’s annual compilation of health statistics for its 194 Member States. The series is produced by the WHO Department of Information, Evidence, and Research, of the Health Metrics and Measurement Cluster, i...

whitepaper

Jun 06, 2018

The aim of this White Paper is to identify inequalities in government policies towards opioids that contribute to the inadequate treatment of pain. It calls for their replacement with policies that will support doctors and patients in their efforts t...

whitepaper

Jun 05, 2018

When choosing an EMR system, you need to consider what you will be charged for and when, in addition to how much. This highly visual guide offers a clear explanation of how various pricing models work, along with actual pricing for popular EMR and Pr...

whitepaper

Jun 05, 2018

Ever participated in one of those benchmarking exercises? You know what I mean. When a (usually) fresh-faced consultant asks lots of questions and fills in a spreadsheet comparing what you do with your competitors. Well, beware. Trying to copy and fo...

whitepaper

Jun 05, 2018

Millennials are quickly becoming the dominant health care consumers, both for themselves, their families and as caregivers. Having grown up in a technology-first environment, however, they are increasingly dissatisfied with the static nature of healt...

whitepaper

May 25, 2018

The number of users and devices requesting access to applications is growing exponentially, and enterprises are scrambling to adapt their authentication and authorization infrastructure to deal with this fast growth. REST APIs are a critical new appl...

whitepaper

May 22, 2018

According to a recent study conducted by AmericanEHR, nearly 40 percent of physicians would not recommend their EHR solution to another provider; only slightly fewer said they would not purchase the same software again. Conversely, a study conducted ...

whitepaper

May 15, 2018

Manufacturing of sterile aqueous suspensions requires the thorough understanding of the factors that influence their physical and chemical stability. Particle morphology of the active pharmaceutical ingredient (API) plays a key factor in drug product...

whitepaper

May 06, 2018

Selecting the right site is the single most crucial decision
you’ll make about your next clinical trial. And perhaps the
single most important consideration in selecting a site is
whether it can make its enrollment. Many do...

whitepaper

May 05, 2018

Transitioning patients between outpatient, inpatient, post-acute and home settings can be a major challenge for hospitals. For organizations participating in value-based reimbursement models, it can also be costly. This case study examines how Holyok...

whitepaper

May 05, 2018

Commonwealth Physicians (Commonwealth)* is a physician-owned multi-specialty, the multi-location practice that serves more than 500,000 patients and is comprised of 25 practices and nearly 100 primary care providers. For Commonwealth Physicians, the ...

whitepaper

May 04, 2018

Supplier Relationship Management (SRM) is not a new concept, but it has been growing in importance. The theory is that SRM helps enterprises drive value in both recessionary periods – like that of the last few years – by enabling cost red...

whitepaper

Apr 25, 2018

Tissue pathology is at the core of various aspects of the pharmaceutic pipeline. Digital pathology is a technology that converts glass microscope slides with tissue samples into whole slide digital images, which can be used to identify, quantify, and...

whitepaper

Apr 25, 2018

Automated image analysis systems that provide detailed morphological information are rapidly replacing manual microscopy as the most effective method of characterizing both particle shape and size. These sophisticated new instruments use the latest t...

whitepaper

Apr 19, 2018

As plastics continue to enter the environment, understanding their global impact is vital to addressing microplastic pollution. Since its emergence as an environmental and potential human health threat, researchers have strived to develop tools for a...

whitepaper

Apr 05, 2018

Preventable chronic diseases such as diabetes, cardiovascular disease, and cancers are responsible for over 40 of the 56 million annual deaths worldwide (7 out of every 10 deaths). Our medical communities spend vast resources battling complications o...

whitepaper

Apr 04, 2018

There is currently a half-dozen different insulin analogues on the market. These differ from each other and from natural insulin by just a few amino acids but exhibit markedly different pharmacokinetic and pharmacodynamic properties. Liquid chromatog...

whitepaper

Mar 28, 2018

RNA sequencing (referred to as RNA-Seq with traditional sequencing technologies) has led to unprecedented advances in all fields of biology and medicine. It has been an invaluable tool for the study of human genetics and the pathology associated with...

whitepaper

Mar 20, 2018

Aqueous cleaners are typically formulated to ensure maximal cleaning performance by using key ingredients such as surface active agents (surfactants) excellent wetting agents that allow the cleaning solution to penetrate into crevices while getting u...

whitepaper

Mar 16, 2018

Chronic pain, the kind of pain a person wakes up with every morning and goes to sleep with every night, has a standard of care that is often incomplete and sometimes inaccurate. Chronic pain treatment often revolves around drug therapy and managing s...

whitepaper

Mar 14, 2018

While the co-rotating, intermeshing TSE is more commonly used in pharmaceutical R&D and production, the counter-rotating, intermeshing TSE is a viable tool to successfully process these formulations. Energy input must be strategically balanced to...

whitepaper

Mar 10, 2018

This paper will discuss the aspects of bioburden reduction in a manufacturing area or cleanroom during operational shutdown or for routine maintenance scheduling. Relevant regulatory requirements are overviewed, along with the factors constituting as...

whitepaper

Mar 01, 2018

About Clinical Research Management, Inc. Clinical Research Management (ClinicalRM) is not only involved in the testing of new antibiotics in Phase I, II, III studies, monitoring protocol development, site selection, and assistance with FDA approvals,...

whitepaper

Feb 21, 2018

Despite a recent global economic downturn, the world pharmaceutical market is currently estimated to be valued at around $300 billion and rising, according to the World Health Organization (WHO). In a recent post, the WHO states that more than a thir...

whitepaper

Feb 18, 2018

What if we could focus interventions on the exact group that can be most impacted? Target those that can benefit most from a particular series of actions? Identify transient patients so they could be intensely targeted before they move on? Effectivel...

whitepaper

Feb 18, 2018

At first, users had to remember different passwords for each application, and provisioning and managing accounts was a cumbersome, manual IT task. In addition, compliance with the Health Insurance Portability and Accountability Act (HIPAA) in Heal&rs...

whitepaper

Feb 13, 2018

The pharmaceutical industry is not short of challenges patent cliffs, regulatory scrutiny, and R&D productivity, as well as a complex supply chain. Pharmaceutical products see several changes of hands from the manufacturers to distributors to dis...

whitepaper

Feb 02, 2018

Healthcare providers face a variety of resource, compliance, security, cost, reimbursement, and integration challenges that have not only strained hospital IT departments but also have affected they way clinicians provide care

whitepaper

Jan 20, 2018

There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. For primary pack choices, there are traditional vials, ampoules, cartridges, pre-filled syringes and complex containers such as t...

whitepaper

Jan 12, 2018

Welcome to Pharmaprojects’ 2017 review of trends in pharmaceutical R&D. For around a quarter of a century now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’ll look at how the land li...

whitepaper

Jan 10, 2018

This whitepaper addresses value-based health care as a driver of Population Health Management (PHM), the integral role of pharmacy-based Population Health Management, and strategies for optimizing patient care capacity to improve health outcomes and ...

whitepaper

Jan 03, 2018

Will the 21st Century Cures Act further its aim to boost drug and device development in 2018? That's one of the questions the life sciences industry and attorneys are asking for the new year. The law provides extra money for research and developm...

whitepaper

Nov 23, 2017

The affordability of healthcare and biopharmaceutical drugs is a top concern for Americans. It is often asserted that promoting innovation and affordable drugs are conflicting goals. New innovations, however, often provide improved health that was no...

whitepaper

Nov 01, 2017

Near-infrared (NIR) spectroscopy is an important technique for materials checking at various stages of the manufacturing process but is particularly useful at the raw materials inspection stage. Raw materials come in a variety of physical forms inclu...

whitepaper

Oct 30, 2017

Medication errors remain an unnecessary public health menace. While industry awareness of the problem has existed for some time, efforts to reduce the incidence and impact of medication errors have not yet yielded much success. Consequently, the sign...

whitepaper

Oct 18, 2017

Since Haemophilus influenzae became the first organism to have its entire genome sequenced in 19951 , there are now thousands of completed genomes covering archaea, bacteria and eukarya. However, the term ‘completed genome’ (or sometimes ...

whitepaper

Oct 17, 2017

The fully realized vision of precision medicine includes the capability to rapidly diagnose, sequence and develop a personalized treatment plan based on combined analysis of genotype, phenotype, environmental, clinical and behavioral data. Precision ...

whitepaper

Oct 17, 2017

Management of medication delivery through lyophilization - freeze-drying - is a crucial enabling process technology for many important parenteral drugs. Close to 50% of biopharmaceuticals, including enzymes, proteins and monoclonal antibodies, must b...

whitepaper

Oct 16, 2017

The Government and the Swedish Association of Local Authorities and Regions, together with a broad set of pharmaceutical actors, have agreed to continue to build on and enhance the work that has been in progress for several years under the National P...

whitepaper

Oct 09, 2017

Polymun offers the development of liposomal formulations for all kinds of pharmaceutically active ingredients and vaccine antigens. A broad spectrum of analytical methods has been established for this purpose. Polymun produces GMP material including ...

whitepaper

Oct 05, 2017

Pharmacometrics, which includes the science of pharmacokinetics-pharmacodynamics (PK-PD), is one of the most commonly misunderstood, misused, and under-appreciated resources available to drug developers. In the past PK-PD was an afterthought, but tod...

whitepaper

Sep 27, 2017

Healthcare information technology has quickly become one of a clinician’s most powerful instruments. The implementation of technology to automate the collection and documentation of patient information, such as vital signs, continues to expand ...

whitepaper

Sep 21, 2017

BlockRx is a series of initiatives presented by iSolve, a privately owned Blockchain solution provider for the Life Sciences Industry. The mission of BlockRx is to interconnect systems that do not readily communicate, establish data provenance that s...

whitepaper

Sep 20, 2017

Fascinating developments within the biopharmaceutical sector have been grabbing industry headlines for years now. The field is exciting and developing rapidly. However, the reality is that small, synthetic molecules remain critically important to bot...

whitepaper

Sep 11, 2017

Life Sciences companies are attempting to improve compliance and manufacturing efficiency while they drive to grow revenue and margins. However, current market conditions are creating substantial headwinds to attaining these targets. S

whitepaper

Sep 01, 2017

The Drug Supply Chain Security Act (DSCSA) has been on the mind of pharmaceutical manufacturers since it was enacted in 2013, and the latest requirements are rapidly approaching. Beginning in November 2017, manufacturers will be expected to mark thei...

whitepaper

Aug 29, 2017

A revolution is occurring in cancer treatment, based on new insights into the biology of cancer, and resulting in dozens of new drugs on the market or in the development pipeline. Many of these new drugs are “targeted” therapies that are ...

whitepaper

Aug 23, 2017

The development of novel therapeutic products involves a complex network of internal departments and external partners. Different groups across Process Development organizations typically use a variety of approaches to capture, manage, analyze and re...

whitepaper

Aug 01, 2017

This white paper arises out of the Pink Ribbon drugs funding & trials conference, held at the faculty of pharmaceutical medicine on 23 March 2017 (full programme provided on page 13-15). The general theme to emerge from the conference is that the...

whitepaper

Jul 04, 2017

At Lipotype our expertise are lipids, lipid metabolism, lipid chemistry and lipidomics. Therefore, statistical analysis is always done with this knowledge as a basis. We treat lipids not as isolated entities but as a metabolic network with substructu...

whitepaper

Jun 21, 2017

Silicones are used in pharmaceutical applications as part of formulations, as well as during manufacturing and in packaging. The term ‘silicones’ encompasses a large number of compounds based on polydialkylsiloxanes. The most common are t...

whitepaper

Jun 21, 2017

Outsourcing pharmacovigilance activities is a standard business practice in a continuously expanding market segment. In the past, outsourced safety services were limited due to concerns about confidentiality, data security, and liability in cases of ...

whitepaper

Jun 20, 2017

Drug manufacturers currently do not have an effective way to securely, transparently, and rapidly track the provenance of drugs or to access the data required to combat counterfeit drug sales. (1) As a result, they are unable to decrease the time and...

whitepaper

Jun 20, 2017

For the 2017 survey,the maximum sample size- the number of countries and territories with at least one FIP member organisation or candidate member organisation at the time of the survey.

whitepaper

Jun 14, 2017

The most eye-catching change in innovation for 2016 from the previous year was the fall in the number of new agents approved by the FDA, 22 for 2016 versus 41 and 45 in 2014 and 2015 respectively. Five agents being licensed at the end of 2015, plus t...

whitepaper

Jun 12, 2017

In the pharmaceutical environment, and especially in the research and development field, the quality of the medicine is a critical step as it is facing challenges with increased? demand from the regulatory affairs to improve the quality of a pharmace...

whitepaper

Jun 08, 2017

Manufacturers of pharmaceuticals, drug delivery systems, and biomedical devices have come under growing pressure to perform sensitive and accurate analytical studies to detect, identify, and quantify extractable and leachable compounds (E&Ls). E&...

whitepaper

May 22, 2017

Price gouging in the US pharmaceutical drug industry goes back more than three decades. In 1985 US Representative Henry Waxman, chair of the House Subcommittee on Health and the Environment, accused the pharmaceutical industry of “gouging the A...

whitepaper

May 18, 2017

In the field of dosing and filling in the pharmaceutical industry, one usually thinks of waterlike, non-viscous products such as solutions used for injecting. For the most part, these can be filled with a high degree of process reliability using hose...

whitepaper

May 18, 2017

The use of aqueous cleaning in pharmaceutical manufacturing can provide numerous benefi ts in terms of effectiveness, minimal surface residue, and easier cleaning validation. Virtually any pharmaceutical manufacturing equipment — from tablet presses...

whitepaper

May 17, 2017

Access to medicines for cancer patients is crucial for providing high quality care. However, cancer medicines shortages are a problem affecting countries across Europe. These shortages occur when the supply of medicines, identified as essential by th...

whitepaper

May 17, 2017

Access to medicines for cancer patients is crucial for providing high quality care. However, cancer medicines shortages are a problem affecting countries across Europe. These shortages occur when the supply of medicines, identified as essential by th...

whitepaper

May 05, 2017

This IDC White Paper, sponsored by Pure Storage, discusses important healthcare IT storage needs for the growing provider market, focusing on how all-flash storage solutions can be used to provide faster access to patient data. Patient data includes ...

whitepaper

Apr 04, 2017

Healthcare in the United States is and always has been a complex system. This complexity is ever increasing as value-based purchasing and population health management transform our hospital-centric industry into one focused on the continuum of care.`...

whitepaper

Mar 15, 2017

Pharmacy’s role is expanding from supply chain to primary care, from intermediary and retailer to expert advisor in health and wellness. From the developing nations of India and China to more-developed markets like the UK, this evolution is acc...

whitepaper

Feb 11, 2017

The annual Chemical Sciences and Society Summit (CS3) brings together the best minds in chemical science research from around the world and challenges them to propose innovative solutions for society’s most pressing needs in the areas of health...

whitepaper

Jan 30, 2017

Prescription opioid misuse and opioid use disorder (OUD) are significant and growing public health problems in the United States (U.S.) that impact stakeholders across the healthcare sector, including private, employer-sponsored, and public health pl...

whitepaper

Jan 26, 2017

This report is an update on the pharmaceutical outsourced manufacturing sector with the last Results’ report published in 2013. By 2015, the global Pharmaceutical market reached $1.11 trillion and is expected to continue growing at approx. 5.5% per a...

whitepaper

Jan 06, 2017

New guidelines governing the analysis of elemental impurities in pharmaceuticals are being implemented.Toxic heavy metals and residual metal catalysts may exist in the raw materials of Active Pharmaceutical Ingredients (APIs) or be added during the m...

whitepaper

Dec 27, 2016

New guidelines governing the analysis of elemental impurities in pharmaceuticals are being implemented. Toxic heavy metals and residual metal catalysts may exist in the raw materials of Active Pharmaceutical Ingredients (APIs) or be added during the ...

whitepaper

Dec 20, 2016

Pharmaceutical industry interest in biopharmaceuticals, cell therapies and, more recently, biosimilars has increased significantly1,2. In addition to targeting and treating disease more effectively than small molecule medicines, such products have th...

whitepaper

Oct 03, 2016

To manage chronic medical conditions, real-time monitoring of disease-specific physiologic metrics is becoming an important part of standard of care, and smartphone technology is making it possible. Existing smartphone interfacing devices now record ...

whitepaper

Sep 19, 2016

This White Paper reviews the empirical evidence on pharmaceutical regulation and private investments from the health economics and health policy literature. First, off-label use is defined and the rationale for government regulation is reviewed. The ...

whitepaper

Sep 14, 2016

“Digital born data” is found everywhere in regulated Good Practice environments for laboratory (GLP), clinical (GCP), and manufacturing (GMP) purposes, e.g., (GXP). Paper documents are also scanned into digital format (PDF) for storage an...

whitepaper

Aug 03, 2016

A brand name drug is a medicine that’s discovered, developed and marketed by a pharmaceutical company. Once a new drug is discovered, the company files for a patent to protect against other companies making copies and selling the drug. At this ...

whitepaper

Jul 28, 2016

If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, tr...

whitepaper

Jul 20, 2016

the designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the european observatory on Health Systems and Policies concerning the legal status of any country...

whitepaper

Jul 12, 2016

RecunnectLtd takes the pleasure to invite professionals involved in pharmacovigilance, risk assessment and management, clinical research, data analysis and related fields for a two day conference on Pharmacovigilance to enable them to gain a vantage ...

whitepaper

Jun 27, 2016

Modern Pharmaceutical Drug Analysis essentially involves as a necessary integral component even greater horizons than the actual prevalent critical analysis of not only the active pharmaceutical substances but also the secondary pharmaceutical produc...

whitepaper

Jun 22, 2016

Pharmaceutical manufacturing is shedding its “poor cousin” image and gaining in importance relative to R&D and marketing. Decades of regulatory and industry standard practice in manufacturing are being reworked to help push operating ...

whitepaper

Jun 22, 2016

The rapidly expanding specialty pharmacy market has created unique challenges for pharmaceutical manufacturers looking to obtain dispensing, adherence, and switching data for specialty drugs. Access to timely, anonymized, longitudinal patient data fo...

whitepaper

Jun 22, 2016

Since the time of blockbuster drugs and mirrored sales teams a decade ago, pharmaceutical reps’ access to physicians continues to decline each year. Studies indicate that between 36.5% - 44% of physicians are now being designated as “no a...

whitepaper

Jun 21, 2016

Since eyeforpharma, Barcelona 2015, we have heard industry, vendors, specialists, advocacy groups and patients talking about patient-centricity: what is it? What does it mean for the industry and the wider healthcare environment? What does it mean fo...

whitepaper

Jun 16, 2016

Sustainalytics is an independent ESG and corporate governance research, ratings and analysis firm supporting investors around the world with the development and implementation of responsible investment strategies. With 14 offices globally, Sustainaly...

whitepaper

Apr 13, 2016

Nanoparticle Tracking Analysis represents a rapid and information-rich multi-parameter nanoparticle characterization technique allowing the user to obtain number frequency particle size distributions of polydisperse nanoparticulate systems. It has re...

whitepaper

Apr 08, 2016

It is well established that the use of nanotechnology in medicine and more specifically drug delivery is spreading rapidly. Driven by the diminishing rate of discovery of new biologically active compounds that can be exploited therapeutically to trea...

whitepaper

Dec 14, 2015

The bulk physical properties such as strength and toughness of materials such as synthetic and natural polymers, or the activity and efficacy of proteins and biopharmaceuticals are strongly dependent on their molecular properties.

whitepaper

Nov 13, 2015

The evolution of the generic drug market in recent decades has introduced many benefits to the healthcare industry lower pharmaceutical costs and greater consumer access to needed medicines. By offering the bioequivalent product of a brand name drug ...

whitepaper

Jul 22, 2015

This report sets out the key challenges, risks and opportunities associated with establishing a national medicinal cannabis scheme in Australia. The report is comprised of several sections, each intended to serve as a reference for future policy disc...

whitepaper

Jul 22, 2015

Published in June 2007 this paper highlights a number of issues that will have a major bearing on the industry over the next 11 years. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the f...

whitepaper

Jul 15, 2015

Clinical development modernization efforts have become essential as clinical trials have experienced increased expectations, costs and design complexity. The utilization of historical clinical data can enhance drug research and development by refinin...

whitepaper

Jun 24, 2015

The pharmaceutical marketplace is undergoing huge changes, as we indicated in “Pharma 2020: The vision”, the White Paper PricewaterhouseCoopers published in June 2007.1 These changes will have a major bearing on the kind of business model...

whitepaper

Jun 23, 2015

The pharmaceutical industry is unique with its extensive regulations. Decisions concerning quality assurance are usually made on the basis of regulatory requirements and guidelines. Quality control takes a central role in the pharmaceutical industry....

whitepaper

May 05, 2015

Biopharmaceutical drug development has been experiencing one of its most productive periods in recent history. During the past decade, the total number of new chemical and biologic entities in the R&D pipeline has been rising 6% each year and now...

whitepaper

Mar 11, 2015

This report exposes the excessive lobbying influence of the pharmaceutical industry on EU decision-making. Big pharma enjoys semi-systematic privileged access to decision-making in Brussels, facilitated by its vast lobby expenditure, complex web of a...

whitepaper

Jan 03, 2015

Interpol estimates the annual turnover from pharmaceutical crime as USD 75 billion worldwide.1 In the US alone, the number of IPR-related seizures in the pharmaceutical and personal care industries amounted to USD 72,939,399, or 6% of the market shar...

whitepaper

Oct 29, 2014

Prescription drugs have become a key factor in workers’ compensation. Accounting for one of every six medical dollars, pharmacy’s impact on disability duration, return to work and claim settlement outweighs the benefit’s dollar expe...

whitepaper

Oct 29, 2014

This guideline is intended to help manufacturers implementing modern quality systems and risk management approaches to meet the requirements of quality products to ensure their intended purpose and to protect the public health. The requirement in thi...

whitepaper

Jun 17, 2014

Annual spending by the pharmaceutical industry is 5.5 times greater than the defence and aerospace industries 5 of the 11 leading global R&D firms were research-based pharmaceutical companies In 2014, pharmaceutical industry gross value added was...

whitepaper

Oct 26, 2013

This White Paper explains the science and current practice of drug testing in various contexts and outlines the ways in which drug testing can be used more effectively in medical practice. We focus on ways that physicians, other health care providers...

whitepaper

Jul 17, 2013

The World Health Organization describes pharmacovigilance as the process of detecting, assessing, understanding, and preventing adverse events associated with medicinal products, with the aim of enhancing patient care and safety.1 While the goal of p...

whitepaper

Jun 19, 2013

Understanding the most appropriate regulatory compliance solution extends beyond pure technological functionalities; it requires intimate understanding of policies and procedures required to achieve meaningful compliance with regulations, worldwide. ...

whitepaper

Oct 30, 2012

Congress created the 340B program in 1992 to help uninsured indigent patients gain better access to prescription medicines. To achieve that goal, Congress created a program that requires pharmaceutical manufacturers to provide discounts on outpatient...

whitepaper

Jun 20, 2012

Rare genetic disease research is an important area of unmet medical need. There are thousands of untreated rare diseases caused by tens of thousands of individual genetic defects, and each presents with unique clinical manifestations. To meet the cha...

whitepaper

Jan 17, 2012

A milestone in terms of the introduction of new regulations in the campaign to combat counterfeiting in the pharmaceutical industry. However, even before this date, global manufacturers had already started to introduce new coding measures to increase...

whitepaper

Nov 02, 2011

This white paper arises from two workshops held at the NIH to review the state of the art in systems biology and pharmacology. Workshop participants included leaders in the two fields working in academia, industry and government (including the FDA). ...

whitepaper

Dec 16, 2004

Pharmacy benefit managers (PBMs) historically have used practices such as broad pharmacy networks and pricing models that rely on several revenue sources. Recently, new approaches have placed substantial emphasis on transparency, suggesting that conc...

whitepaper

Oct 27, 2004

“The FDA oversees the quality of drug products using a two-pronged approach involving review of information submitted in applications as well as inspection of manufacturing facilities for conformance to requirements for current Good Manufacturi...

whitepaper

Process equipment used in the healthcare industry follow rigid specifications for accuracy, consistency and cleanliness.These regulations ensure that end products are safe, pure, and effective. In particular, mixing equipment employed in the producti...

whitepaper

Industry concern about counterfeiting, diversion, mishandling, mislabeling, and unintended or mistaken administration of prescription drugs is mounting at an unprecedented pace. Stakeholders at all junctures of the pharmaceutical supply chain from po...

whitepaper

Collectively rare diseases comprise a large segment of the global population. Developing effective treatments to combat these diseases demand heavy resources from biopharmaceutical companies - both monetary and scientific. Even though these diseases ...

whitepaper

The notable success of imatinib for the treatment of chronic myeloid leukemia and trastuzumab for the management of HER2-positive breast cancer patients has generated great enthusiasm for the delivery of more effective and safer treatment to patients...

whitepaper

The Food and Drug Administration (FDA) has a system, known as expanded access, to provide investigational drugs outside of clinical trials. Critics of this program have said that it is cumbersome and discourages many patients and physicians from appl...

whitepaper

Patients with Alzheimer’s disease suffer from progressively worsening memory impairment, thought processes, and behaviors. Alzheimer’s disease symptoms manifest primarily in short-term memory loss: patients forget names, dates, or events;...

whitepaper

Handheld Raman is an attractive ID method because it provides a portable measurement that can distinguish different concentrations of active pharmaceutical ingredients (API) in drug product (DP) doses and placebos with little or no sample preparation...

whitepaper

Immunotherapies are being touted both in scientific literature and the general media as the most promising advances in cancer treatment in decades. Indeed, newly approved drugs are improving survival dramatically for patients with many difficult-to-t...

whitepaper

Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies to form with groups representing patients and families. inVentiv Health Public Relations Group interviewed dozens of pat...

whitepaper

The increasingly busy schedule of physicians and healthcare providers has led the pharmaceutical industry as a whole to adopt a Closed Loop Marketing (CLM) strategy. However, many pharma companies struggle with implementing and maintaining an effecti...

whitepaper

Medical information (MI) teams at pharmaceutical and medical device companies primarily respond to inquiries about the company’s products. Inquiries can originate from healthcare providers, patients, scientists or anyone interested in information abo...

whitepaper

The more sales reps know about the physicians in their territory, the better their leverage in gaining access to them, which is why one top 10 pharmaceutical company decided to focus on enhancing field intelligence. They turned to LexisNexis Health C...

whitepaper

It is not surprising that mostly small to medium sized companies seek the help of specialist consultancies to find commercial partners or find in-licensing opportunities. Large pharma is in the attractive position that they get thousands of unsolicit...

whitepaper

Records and signatures in regulated environments can be either created on paper or electronically. In the past, the use of paper has been favored over electronic records and signatures. Advantages of electronic records compared to paper-based records...

whitepaper

From a patient perspective, hub services can often be a lifeline to managing complicated, chronic conditions. Creating a solution that supports patients who rely on “middle-ground” specialty medications is a necessity for an area that is becoming a l...

whitepaper

Tubing used in pharmaceutical and biotech applications has particular requirements. Among them are the ability to withstand sterilization processes, the delivery of favorable test results regarding extractable substances, and the absence of animal de...

whitepaper

Surely, we cannot consider a manufacturing plant in isolation but need to see it in its context of a seamless, endto-end value chain from suppliers, through an internal and external manufacturing ecosystem, and all the way to the patient. This is not...

whitepaper

With growing cost pressures and new regulations, manufacturers and quality managers in the pharmaceutical industry are always looking for ways to improve their processes and procedures. A new electronic batch record solution enables complete paperles...

whitepaper

With a reputation as one of the original pioneers of containment technology, Powder Systems Limited (PSL) hold a wealth of experience designing and engineering advanced containment processes, supplying customized process equipment to the pharmaceutic...

whitepaper

The use of aqueous cleaning in pharmaceutical manufacturing can provide numerous benefits in terms of effectiveness, minimal surface residue, and easier cleaning validation. Virtually any pharmaceutical manufacturing equipment, from tablet presses to...

whitepaper

Since the advent of the commercial Internet, digital technologies have empowered consumers worldwide, leading them to play an active and demanding role with the companies with which they do business. The rules of engagement have changed: By using the...

whitepaper

Industry experts discuss how digital health is poised to disrupt the pharmaceutical industry and revolutionize the clinical trial process and medication adherence. Digital health – the use of wearables, sensors and applications to remotely coll...

whitepaper

The PII ranks companies by their ability to bring products from Phase I/II to market and commercialize them successfully, and utilizes a range of clinical, regulatory and commercial metrics to do this, ranging from the corporate level down to individ...

whitepaper

The pharmaceutical industry faces complex issues in ensuring patient safety. It must test and provide safety and efficacy profiles on its prescription drugs during clinical trials and throughout the product lifecycle. It must adhere to strict quality...

whitepaper

The power and potential of outsourcing has long been recognized as a core enabler of business growth. Yet while the pharmaceutical industry has been making strides in this area, there is still some way to go to realize the full potential; only in the...

whitepaper

What parallels can we draw between portugal’s 500-year history of maritime explorations and global pharmacy,healthcare and the international pharmaceutical federation .

whitepaper

The evolution from scientific hypothesis to approved and marketed medicine is a lengthy and arduous process that typically spans many years of research and development. to understand clinical research and data flows.

whitepaper

Today, pharmaceutical companies need to produce a higher number of therapeutics for smaller patient populations. But as the FDA points out, companies have not invested in manufacturing infrastructure and practices to meet these challenges. The goal o...

whitepaper

Within the highly regulated pharmaceutical industry, pipeline activity is fueled by M&A and drug development. This process is drawn out by lengthy phases of research and discovery as well as risky clinical trials. For pharma companies (and by ext...

whitepaper

This white paper provides an introduction to vaccine safety science and policy in the United States. Section “I” discusses how Congress granted pharmaceutical companies immunity from liability for vaccine injuries and transferred all resp...

whitepaper

Pink Ribbon is a growing international network for breast cancer prevention and cure, seeking to help eliminate all breast cancer-related deaths. In the UK, its current focus includes an annual conference called the Breast Cancer Forum, held in assoc...

whitepaper

In our 2012 report, we assessed the magnitude of the medication adherence problem in chronic conditions and gauged its impact on pharmaceutical revenues. Our findings showed estimated revenue losses of $188 billion in the US and $564 billion globally...

whitepaper

As organizations implement a patient-centric model, they will discover that there is an urgent need to innovate and find effective healthcare solutions. While the Research and Development (R&D) function is becoming complex in terms of portfolio a...

whitepaper

Soaring drug development costs, patent expiration, and reduction in the number of blockbuster drugs are driving pharma companies to look at IT-enabled productivity.

whitepaper

Micronutrients play a critical role in overall nutrition and health. This is highlighted by the plethora of continuous research published in high profile scientific journals focused on the benefits of vitamins and minerals. However, evidence shows th...

whitepaper

The Drug Quality and Security Act, a United States bill passed in 2013, calls for manufacturers to make prescription drugs traceable on a per-unit basis. Manufacturers will need to mark each package with a serial number or machine-readable code in or...

whitepaper

GlaxoSmithKline (GSK) executives made industry news in 2011 by announcing that their sales reps would no longer have their at-risk compensation based on prescription (Rx) volume generated by physicians.1 The traditional proportion of base-salary to a...

whitepaper

The purpose of this white paper is to provide an overview of the applicability of public procurement legislation in the healthcare sector, and more specifically the challenges it sets to the pharmaceutical industry.

whitepaper

Branding means a lot of different things to a lot of different people, but in its simplest form, a name is the face of a brand. Just as people have names. Something we’re recognized by and called—so do pharmaceutical brands

whitepaper

Pharmaceutical drug naming and branding can seem like a complicated mystery to most consumers. Because of extensive research and regulations, medication names are getting less and less intuitive but marketed more than ever. It wasn’t too long a...

whitepaper

Cameras have been playing an increasingly important role in medicine for many years now. Regardless of whether you‘re looking at medical devices, laboratory automation or the operating room, in almost every field there is a multitude of everyda...

whitepaper

There is hardly another product that reaches consumers or patients for which packaging requirements are as varied as for pharmaceutical products. The »Poisons Prevention Packaging Act« (PPPA) enacted in the United States back in 1970 addr...

whitepaper

Although it is one of the oldest techniques in the pharmaceutical industry for the preservation of unstable materials, there still is an increased demand for lyophilized products and equipment. To accommodate such a growth, the freeze-drying process ...

whitepaper

Service Oriented Architecture (SOA) has radically changed the application integration landscape. However, the need for intelligent service discovery based on invocation context and service capability is still a challenge. Ontology-based techniques ar...

whitepaper

The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible for 70% of overall drug spending growth during this timeframe.

whitepaper

Rare genetic disease research is an important area of unmet medical need. There are thousands of untreated rare diseases caused by tens of thousands of individual genetic defects, and each presents with unique clinical manifestations.

whitepaper

Every day, healthcare organizations dispense a broad spectrum of medications. An essential yet often overlooked aspect of this drug delivery process is what to do with any unused medications.

whitepaper

Sales of pharmaceuticals in China are already the third highest in the world, and China is likely to become the world’s second-largest drug market within the next year. Multinational pharmaceutical corporations cannot afford to underperform in ...

whitepaper

Metastatic and primary tumors are known to respond differently to chemotherapy. Therefore, when establishing drug efficacy it is important not to rely only on experiments in primary tumor models but to also study the test compound in metastasis model...

whitepaper

A common problem statement in the pharmaceutical industry is low oral bioavailability of drug candidates with poor aqueous solubility. The literature suggests that a significant majority of new drug candidates are in the Biopharmaceutics Classificati...

whitepaper

Value-based pricing (VBP) of pharma products has exciting potential to help improve patient outcomes – at an affordable cost. The concept of VBP has been around for some time, but healthcare stakeholders are still grappling with what it means f...

whitepaper

Pharmaceutical Companies have to contend with challenges stemming from supply chain security lapses (Resulting in theft, diversion, and product RE calls), Counterfeiting stringent regulation.

whitepaper

Global pharmaceutical companies lose an estimated $75 billion annually to counterfeit, gray market and stolen product. Impending regulations aimed at protecting public health, intellectual property and national security will require pharmaceutical, m...

whitepaper

Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities to create value for our pharmaceutical partners by providing a complete portfolio of integrated drug delivery servi...

whitepaper

To meet your requirements even better, we have created a specific range of drug delivery technologies, EUDRATEC. For both EUDRAGIT and EUDRATEC we offer tailor-made development services for commercially viable formulations. We develop and manufa...

whitepaper

The launch of the Center for Drug Evaluation and Research (CDER) Office of Pharmaceutical Quality (OPQ) is a milestone in FDA’s efforts to assure that quality medicines are available to the American public. As a new super-office within CDER, OP...

whitepaper

Quality assurance and control play an essential role in the pharmaceutical manufacturing process, by ensuring that patients are provided with medications that are safe, effective, and produced at a high level of quality.

whitepaper

A great source of worry in industrialized societies is disease or health problems caused by taking medicines that are in poor condition or are subject to a health alert. Society expects that manufacturers, distributors, and employees should be in con...

whitepaper

This document is Copyright 2015 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided that this copyright notice is not removed. It may not be sold for profit or used in commercial doc...

whitepaper

Provide a high-level description of the issues experienced with current data management practices involving the Medicaid Drug Rebate Program and the functions related to drug rebate invoicing, billing quantity/pricing discrepancies, and the reconcili...

whitepaper

The information contained in this document is the proprietary and exclusive property of the National Council for Prescription Drug Programs, Inc. (NCPDP) except as otherwise indicated. No part of this document, in whole or in part, may be reproduced,...

whitepaper

One of the greatest challenges in drug development is the high attrition rate obtained in Phase 2 clinical trials, resulting in significantly elevated R&D costs and time. In fact, approximately 80% of new drugs that move into Phase 2—the ph...

whitepaper

The current model of drug development has become economically unsustainable. According to Tufts Center for the Study of Drug Development (CSDD), the cost of bringing a new drug to market now tops $2.6 billion and can take up to 15 years, with less th...

whitepaper

The use of modeling and simulation (M&S) in drug development has evolved from being a research nicety to a regulatory necessity. Today, modeling and simulation are leveraged to some extent, across most development programs to understand and optim...

whitepaper

As a generic drug manufacturer, the goal of your product development program is to demonstrate bioequivalence of your product to the branded product. Often a straightforward trial and error process based on the experience of the formulation team has ...

whitepaper

Population pharmacokinetic (PopPK) analysis has become a key tool for clinical pharmacology experts when working with data from human subjects. In the recent past, new drug registrations utilized pharmacokinetic (PK) information from healthy voluntee...

whitepaper

The Food and Drug Administration (FDA) or other regulatory body-approved drug label is the official description of a drug product and includes what the drug is used for, who should take it, side effects, instructions for use, and safety information f...

whitepaper

Today’s powerful and actively evolving computational tools enable sponsors and regulators to understand potential drug characteristics and subject responses earlier in development, with greater certainty. Model-based approaches support timely, ...

whitepaper

M&S has the ability to influence every phase of the drug development process, including the commercial decisions around the benefits of even bringing a specific drug to market. One of the most important elements of biosimulation is that it allows...

whitepaper

Historically, clinical trials have not examined most pediatric medications.This is due to the ethical and practical challenges of conducting pediatric drug trials. Children are 40% of the world’s population. Yet, regulatory agencies have approv...

whitepaper

The global pharmaceutical sector is embarking on a transformational journey in which the supply chain will play an increasingly strategic role. There will be a need for greater agility and improved speed to market – while ensuring compliance wi...

whitepaper

At its core, the pharmaceutical industry is about improving the quality of people’s lives. But today’s life-saving drugs are often small, high-value items which are easily stolen or diverted. Nearly impossible to authenticate by the end u...

whitepaper

In today’s global pharmaceutical distribution environment, the risks to undermine product safety are significant. Counterfeiting and product diversion are major problems and growing. In 2007 the World Health Organization estimated that drug cou...

whitepaper

Harbisson is one of many patients reaping the benefits of increased connectivity in the healthcare industry. Connected medical device—such as pacemakers and insulin pumps that communicate with other networks and devices over the Internet—...

whitepaper

Assuring the safety and safe use of medical devices in the home is becoming an increasingly important public health issue. The aging of the U.S. population and shifts toward shorter hospital stays continue to make home healthcare more common. With th...

whitepaper

This white paper reviews how the Process Analytical Technologies (PAT) originally developed by the FDA for the pharmaceutical industry can also improve quality and efficiency in medical device manufacturing. The underlying principle of the PAT approa...

whitepaper

Technology has prompted drastic changes in the marketing world over the past decade, and pharmaceutical marketing has not been excluded from this evolution. Faced with shifting consumer and physician media preferences and shrinking budgets - what is ...

whitepaper

As healthcare costs continue to rise, the decision to cover a new drug and provide access to patients who need it lies increasingly in the hands of payers, not physicians. To achieve uptake of its new product, a pharmaceutical company must reorient i...

whitepaper

At EY, we have conducted a survey among healthcare professionals (HCPs) and pharmaceutical companies to understand their perspective of the Medical Council of India’s (MCI) guidelines and the Department of Pharmaceuticals’ (DoP) marketing...

whitepaper

Biopharmaceutical companies make the medicines that save and improve patients’ lives every day. Patients often rely on medicines to keep their symptoms at bay and allow them to continue to work and live healthy, productive lives. Others rely on...

whitepaper

2012 will be regarded by many commentators as one of the most challenging years in the pharmaceutical industry’s history, due in no small part to numerous products facing patent expirations and increased global competition. It is now considered...

whitepaper

Pharmaceutical companies face complex issues that grow more challenging by the day. Healthcare reform and changes in technology, government policy, and consumer expectations are revolutionizing relationships with key stakeholders and impacting operat...

whitepaper

The pharmaceutical industry’s past reliance on blockbuster drugs has evolved to include a focus on developing drugs that treat the unmet needs of smaller patient populations. These niche drugs most often come in the form of biologics, which are...

whitepaper

At Accenture, we believe the healthcare industry’s focus on delivering improved patient outcomes, along with advances in digital technologies, create an environment in which sales reps will be more valuable than ever. With new skills and digita...

whitepaper

Collaborations among academic and government researchers, pharmaceutical and biotechnology companies, regulatory agencies, and patients and their families are crucial to research and development of therapeutics for rare diseases. Industry, academic a...

whitepaper

This white paper has been prepared to initiate a regional dialogue regarding pharmaceutical disposal to the sewer system. It provides an overview of research on pharmaceuticals in the environment and potential actions for consideration during that re...

whitepaper

The pharmaceutical industry is globalizing. Conducting global clinical trials to get a broader and more diverse participant base and expanding into less-saturated developing markets are two significant drivers of globalization. However, this expansio...

whitepaper

The Middle East & North Africa average in our Innovative Pharmaceuticals Risk/Reward Index (RRI) slightly underperforms the global average. The region is highly diverse, with a number of large Gulf States including Saudi Arabia, the UAE, and Kuwa...

whitepaper

Central & Eastern European markets are not considered amongst the most attractive globally for companies looking to launch innovative pharmaceuticals. The Czech Republic, which ranks first in Central & Eastern Europe, is ranked 22nd globally,...

whitepaper

Deaths from drug overdose have been rising steadily over the past two decades and have become the leading cause of injury death in the United States. Every day in the United States, 114 people die as a result of drug overdose, and another 6,748 are t...

whitepaper

America is in the midst of a prescription opioid epidemic. It is estimated that in 2016, 11.8 million Americans, or 4.4 percent of the population, age 12 years and older were nonmedical users of opioids – defined as prescription pain relievers ...

whitepaper

The pharmaceutical sector is at a crossroads. In a heavily disrupted marketplace, characterized by shifting payer attitudes and patient empowerment, neither incremental adjustments nor steady evolution is likely to halt the decline of the traditional...

whitepaper

Prescription drugs sold in retail pharmacies accounted for almost $325 billion or 10% of total healthcare costs in 2015, up 9% from 2014. Such dramatic growth has prompted calls for government intervention to regulate drug prices or otherwise control...

whitepaper

While the term “specialty drugs” has no standard definition, these pharmaceuticals are universally associated with high costs and complex conditions. Unique and highly targeted, such drugs can provide significant improvement or even a cur...

whitepaper

Chronic pain, the kind of pain a person wakes up with every morning and goes to sleep with every night, has a standard of care that is often incomplete and sometimes inaccurate. Chronic pain treatment often revolves around drug therapy and managing s...

whitepaper

Innovative pharmaceutical companies engage in sophisticated strategies to moderate the loss of revenue they will face when generic competitors enter the market. Known in the industry as product lifecycle management, these strategies often rely on the...

whitepaper

The pharmaceuticals industry has struggled to ensure the integrity of its products as they are transferred between the different stops on the value chain from contract manufacturers to wholesalers to dispensers and finally to the patient. This is par...

whitepaper

Recent reports of intrinsic contamination of drug products, including skin antiseptics in the United States have focused attention on the importance of strict adherence to established good manufacturing processes and the application of quality assura...

whitepaper

To address the Zika virus public health threat, the Departments of Health and Human Services and Defense2F 1 are coordinating efforts to help accelerate the development of Zika virus vaccines. Given the need for a vaccine to prevent disease caused by...

whitepaper

The chemical industry is one of the most demanding branches in terms of capital investment, and in view of its complicated production processes and technologies, it requires a highly skilled workforce and considerable investment in research and devel...

whitepaper

In our 2015 facts and figures publication we show how today’s UK chemical and pharmaceutical industry continues to be a vital part of this country’s economy. When the final 2014 figures are published, we expect them to show growth of arou...

whitepaper

Tougher competition and margin pressures create more challenges for the pharma industry in 2016. As more physicians are graduating med school to work directly for a health system instead of opening their own practice, sales force is struggling to ada...

whitepaper

The aim of this guide is to provide you with a basic grounding in the main particle characterization techniques currently in use within industry and academia. It assumes no prior knowledge of particle characterization theory or instrumentation and sh...

whitepaper

Production of protein therapeutics by mammalian cells is the most widely used bioprocess because of its ability to properly produce and fold a recombinant protein. 60-70% of biopharmaceuticals are produced by this bioprocess. Bioreactor parameters af...

whitepaper

Recently a technique called active coating has become more common in the pharmaceutical processing industry. In active coating, the API is included in the tablet’s coating in order to create a multi-step release profile for a single API or to s...

whitepaper

Assay development was done in 384 well format using acetylcholinesterase (AChE) from electric eel and equine butyrylcholinesterase (BChE) as target enzymes. The reactions were started by adding 25 µM substrate solution and quenched by adding 1%...

whitepaper

The calibrant region is determined automatically. The mass calibration function and its ideal polynomial degree are selected automatically using an information criterion to avoid over-fi tting. No manual recalibration is necessary. Novel isotope patt...

whitepaper

Cleaning validation is a requirement in industries such as pharmaceutical manufacturing that adhere to current Good Manufacturing Practice (cGMP) and Quality Systems Regulations (QSR). It is specifi c to the cleaning method and cleaner employed. Simp...

whitepaper

In this report, Sparta Systems, a quality management system (QMS) software provider, examines the results of a Pharmaceutical Technology survey of 160 respondents. The survey was designed to explore the evolving function of pharmaceutical quality man...

whitepaper

Pharmaceutical tablets are coated for a variety of reasons, such as to enhance the appearance, taste, chemical stability, or swallowability of the tablet or to create a particular release profile for the active pharmaceutical ingredient (API). Recent...

whitepaper

One of the most important performance factors of a pharmaceutical product is the bioavailability, i.e. the release of the active compound in a human body. In a solid dosage product (e.g. tablets, powders or capsules), this is directly related to the ...

whitepaper

Adoption of Quality by Design (QbD) principles, regulatory support of QbD, process analytical technology (PAT), and continuous manufacturing are major factors effecting new approaches to pharmaceutical manufacturing and bioprocessing. In this review,...

whitepaper

For certain product types, there is a requirement for testing to determine the absence of certain microorganisms. These specified microorganisms include pathogens and are known as indicator microorganisms. This is due to the fact that they may indica...

whitepaper

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area ...

whitepaper

Introduction: The rise of the super-bug in today’s world, the biodiversity of vital ecosystems is threatened by factors, such as overpopulation, deforestation, mass migrations, war, famine, depletion of natural resources and animal-human intera...

whitepaper

Cleaning validation is a necessary and time-consuming part of manufacturing pharmaceuticals. The validation process can be expedited and the cost reduced if the cleaner supplier can provide support — ultimately allowing pharmaceuticals to get t...

whitepaper

Pharmaceutical and nutraceutical companies have identified product identification (PI) as a major focus to identify and deter counterfeiting and product diversion. This is done through track and trace technologies. To date, the majority of the PI has...

whitepaper

The Oxford Martin School at the University of Oxford is a worldleading centre of pioneering research that addresses global challenges. We invest in research that cuts across disciplines to tackle a wide range of issues such as climate change, disease...

whitepaper

The Multiple Myeloma Research Foundation (MMRF) has the principal goal of accelerating development of next-generation drugs for treating multiple myeloma. By making targeted investments in key research areas such as genomics and epigenetics, the MMRF...

whitepaper

Pharmaceutical, medical device, food & beverage and other companies in regulated markets are required to comply with government regulations, standards and guidelines that are designed to ensure the safety and quality of the products manufactured,...

whitepaper

Another common porous silica material, developed in the late 1990’s at the University of California at Santa Barbara, is SBA-15. Similar to MCM-41, it is relatively low cost to produce and has controllable pore diameters. But relative to MCM-41...

whitepaper

The developmental versatility of pluripotent stem cells (PSCs) offers a powerful approach for directing cell fate, and these cells are a promising source of progenitors and terminally differentiated somatic cells for cell replacement therapy and drug...

whitepaper

In this paper, we sought to lay out the rationale for investing in small cap biotech. There are two key drivers of stock performance of small cap biotech: clinical data and acquisitions. As clinical data must be analyzed on a case-by-case basis, we h...

whitepaper

Pharmaceuticals make a significant contribution to the health and well-being of a population and government policy regarding pharmaceuticals exerts a significant effect on the state of the pharmaceutical market. Governments generally have several obj...

whitepaper

The threat posed by pandemics grows alongside increased globalization and technological innovation. Distant cultures can now be connected in a day’s time, and international trade links global health and economic prosperity. In this report, the ...

whitepaper

Supercritical CO2 has the characteristics of both a liquid and a gas. Like a gas, it diffuses rapidly, has low viscosity, near zero surface tension, and thus, penetrates easily into deep trenches and porosities allowing more effective cleaning. Like ...

whitepaper

Although there are differences in approach across the various regulatory guidelines, the general message is that aseptic processing is key, necessitating floors, walls, and ceilings to be readily cleanable with smooth and rigid surfaces. A system is ...

whitepaper

Although patient treatment has always been personalised by clinicians based upon individual circumstance and medical history, advances in our understanding of the molecular basis of diseases are redefining how diseases are classified and present a po...

whitepaper

Stability testing of a drug substance or a finished product is a vital part of the data package submitted in support of new drug applications or marketing authorisations. The principle ethos of stability testing is to provide evidence to a regulatory...

whitepaper

I n recent years, biopharmaceutical companies large and small have become increasingly reliant on the contract research organisation (CRO) sector and other clinical services specialists to provide research services across the breadth of their R&D...

whitepaper

The manufacture of ethical pharmaceutical products is a critically important process in the provision of healthcare. The process is both technical and carefully regulated, and staff ed by highly trained professionals, and thus the business enjoys hig...

whitepaper

2012 will be regarded by many commentators as one of the most challenging years in the pharmaceutical industry’s history, due in no small part to numerous products facing patent expirations and increased global competition. It is now considered a sou...

whitepaper

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method betwee...

whitepaper

In 2015 Boehringer Ingelheim UK set out on a pioneering journey with two clear aims in mind. One was to define what it means for a pharmaceutical company to be patient centric and, the second, to generate a broad set of internal and external measures...

whitepaper

Product quality, regulatory compliance and operational efficiencies top the long list of business priorities for pharmaceuticals executives, who lead the charge in improving manufacturing and supply chain performance. Investments in areas such as sho...

whitepaper

This chart pack provides facts and figures about prescription medicines and their role in the health care system. Topics include medicines’ impact on health and quality of life, the drug discovery and development process, health care spending and cos...

whitepaper

A modern Integrated Pharmaceutical Development Platform will include builtin requesting capabilities, which provide laboratory managers with early insight into the workload coming their way so they can make more informed scheduling decisions. This re...

whitepaper

The pharmaceutical industry is globalizing. Conducting global clinical trials to get a broader and more diverse participant base and expanding into less-saturated developing markets are two significant drivers to globalization. However, this expansio...

whitepaper

Development, production and quality control in the pharmaceutical industry requires efficient and reliable control mechanisms to ensure the safety and therapeutic effect of the final products. These products can vary widely in composition and applica...

whitepaper

Probiotics, prebiotics, medical food and supplements have been commercially available as OTC products for some time. These products claim to support human health by restoring the balance of the gut microfl ora in favour of ‘benefi cial’ bacteria, mo...

whitepaper

It’s useful to review deal trends periodically to gain insight in how behaviours are changing from the perspective of numbers and value of deals as well as how emphasis shifts from one therapeutic area to another. The majority of small and mid-size d...

whitepaper

This white paper addresses key policy issues, best practices, and key challenges around the pharmaceutical value chain that has an impact on quality of pharmaceuticals available to patients. This white paper also discusses the key stakeholders involv...

whitepaper

In today's pharmaceutical market, it often takes more than a decade and an estimated $2.6 billion to bring a new drug to market. The long development lead time result in approximately 7 to 10 year of patent protection before generic competition launc...

whitepaper

According to the World Health Organization (WHO) definition, a medical device is “an article, instrument, apparatus, or machine that is used in the prevention, diagnosis, or treatment of illness or disease, or for detecting, measuring, restoring, cor...

whitepaper

In the almost 40 years since counterfeiting of pharmaceutical products was recognised as a problem by the World Health Organization (WHO), the industry has waged a constant battle against increasingly sophisticated and organised counterfeiters, with ...

whitepaper

This research study was oriented primarily around the Pharmaceutical and Biotech distribution sector. We focused on the analysis of the current situation and the likely changes in this industry in the next 3 to 5 years. At the outset of the study, we...

whitepaper

Clinical trial drug development requires manufacturers to have the capability to identify, track and manage events in order to stay compliant with protocols and regulatory bodies. A consistent need for quality management is created by the drug develo...

whitepaper

In this paper we envisage future opportunities for value creation by the global biopharma industry. We set these opportunities in the context of an evolving healthcare ecosystem which continually creates new business opportunities and challenges for ...

whitepaper

The drug that can be considered the first precision medicine entered the market in 1998, at a time when the concept was referred to as personalized medicine. Herceptin (trastuzumab) was first used for the treatment of a subgroup of breast cancer pati...

whitepaper

Expenditures in pharmaceutical R&D are higher than ever, and attrition rates have reached 80-90%. The few compounds that make it to market have to carry the cost of the inefficient development process, but hope lies in improving the data that flows i...

whitepaper

The number of challenges for the global pharmaceutical industry is perhaps higher than ever before. Competitive pressures, new stipulations from governments and regulators, products coming off patent and market pricing pressures have combined: pharma...

whitepaper

The Pharma IQ survey depicts the trend of increasingly stringent regulations in the pharmaceutical industry. However, regulations usually only provide broad guidance (e.g. measuring devices must be calibrated) and leave it to the manufacturer to defi...

whitepaper

The European regulators therefore considered that a change was needed. Following recent scandals such as the Poly Implant Prothese ("PIP”) scandali, certain initiatives were having already been taken under the current regime (a) to minimise the risk ...

whitepaper

Empty hard capsules are widely used as a dosage delivery system in the pharmaceutical industry. Gelatin or Hypromellose (HPMC) are used as the shell raw material in the majority of pharmaceutical applications for various reasons including their uniqu...

whitepaper

Traditionally, the healthcare and pharmaceutical industries have followed a conventional supplier-consumer relationship. However, both industries face the same core challenge to deliver better health outcomes at lower cost. This paper discusses chall...

whitepaper

The Pharmaceutical industry holds an undeniably important place in the Life Sciences sector world-wide as it is solely responsible for designing and manufacturing lifesaving drugs and medications. The revenue from this industry alone has almost touch...

whitepaper

Clinical trial consulting and pharmaceutical consulting professionals will benefit by becoming current on adaptive trial design. Gaining in popularity since the early 1990s,1 adaptive trials are those which observe patient outcomes after review of in...

whitepaper

This white paper sets out a roadmap for the successful implementation of a serialization programme applicable to pharmaceutical companies of any size and complexity. It is based on practical experience of implementing serialization for some of the wo...

whitepaper

The role that nanoparticles play in the rapidly developing field of ‘NanoMedicine’ has been discussed previously in Chapter 5. In this Chapter, we review the specificmechanisms by which such nanoparticles are designed and formulated and in which NTA ...

whitepaper

Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex. While the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path and...

whitepaper

Salt form screening (if applicable) is an important early step in inhalation dosage form selection. Approximately 50% of active pharmaceutical ingredients (APIs) in approved products are salt forms,1 and that proportion is slightly higher (approx. 60...

whitepaper

The shift in US health care, from payment based on volume to payment based on value, has sparked interest among payers and pharmaceutical companies in new pricing and contracting arrangements for prescription drugs. The objective of these new arrange...

whitepaper

Regulations allowing compassionate use of investigational drugs have been in effect since 1987, when public anger about the slow pace of approvals for HIV/AIDS drugs resulted in rules allowing greater access to drugs in development. Last year, the FD...

whitepaper

The high failure rate of investigational compounds during drug development, especially in late stages of the clinical development process, is widely seen as a key contributor to the large amount of time and resources necessary to develop new drugs. R...

whitepaper

This White Paper examines the pharmacy profession’s future. It discusses pharmacy’s changing philosophy of practice, factors influencing the evolution of professional roles and responsibilities, preparation for future roles, future leadership and man...

whitepaper

As the U.S Congress considers creating a process that allow the FDA to approve follow -on biologics (FOBs) also referred to as biosimilars on the basis of an abbreviated application by follow on manufacturers there has been heightened interest in und...

whitepaper

Approximately $14 million are provided per year to sponsor companies through the orphan drug grant program, which is applicable to drugs, biologics, medical devices or even medical foods. While this amount may seem small for traditional drugs, it has...

whitepaper

The current pool of existing molecules potentially re-positioned, re-formulated or combined with new technological platforms and services might offer therapeutic alternatives and opportunities for patients and health care systems. Even if this concep...

whitepaper

The first evidence of humans smoking Atropa Belladonna as a cough remedy can be dated back over 4,000 years. Fortunately, technology and expertise in inhalation drug delivery have improved significantly since then, offering better predictability, eff...

whitepaper

it’s been almost 15 years since U.S. direct-to-consumer advertising regulations were loosened. And in those years, the consumer pharmaceutical marketing industry has gone from about $700 million in ad spending to a peak of $5.4 billion in 2006. Spend...

whitepaper

With the rapid growth of the generics market, economic and regulatory pressure on pharmaceutical manufacturers is increasing. In this environment, time to market has become even more critical to shareholder value creation and sustainable profitabilit...

whitepaper

Realizing this potential is neither easy nor assured. The lack of uniformity across EU nations that have had access to biosimilar medicines for almost a decade suggests the underlying elements of achieving the full potential from biosimilar medicines...

whitepaper

Pharmacometrics the use of modeling and simulation to support drug development and assessment decisions has been in use for more than two decades. Today, however, the urgent need for improved R&D productivity within the pharmaceutical sector has high...

whitepaper

Innovative medication formulation encourages adherence for patients with cystic fibrosis for pharmaceutical manufacturers and healthcare providers, patient nonadherence to medication is a significant concern. In the United States alone, research has ...

whitepaper

The pharmaceutical industry is driven to develop oral drug formulations that deliver significant patient benefits. Drug delivery technology can be leveraged to reduce dosing frequency, and therefore, help encourage patient adherence to prescribed the...

whitepaper

Bioassays are required for a variety of purposes in the development and production of biopharmaceuticals including drug candidate selection, product releases, product stability assessment, and comparability to support proposed process changes. Howeve...

whitepaper

One of the more vexing and troubling public health policy issue that has plagued the US pharma industry, yet receiving less deserving public news coverage than other industry stories, has been the existence of chronic drug shortages since the turn of...

whitepaper

The ophthalmology drug segment continues to shine brightly with a number of deals announced in November such as Genentech’s partnering with Novartis to split ex-US rights to Ophthotech’s eye drug, which could be worth more than $1 billion. Allergan, ...

whitepaper

In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics. Identifying patients that will be...

whitepaper

The rise of performance-based managed care contracts is requiring pharma companies to demonstrate drug value in producing health outcomes and/or health economic benefits.1 While performance-based contracts are currently still relatively rare, even wi...

whitepaper

Interestingly, the above quote by Benjamin Franklin epitomizes in many respects the significant daily challenges faced by biopharmaceutical companies – to lengthen and improve the quality of life, while always facing the mortality of patients against...

whitepaper

The power and potential of outsourcing has long been recognized as a core enabler of business growth. Yet while the pharmaceutical industry has been making strides in this area, there is still some way to go to realize the full potential; only in the...

whitepaper

The pharmaceutical industry is transforming the mass production of drugs. More complex compounds, impatient regulators and increasedmarket pressures leave little doubt that manufacturing will no longer be viewed as a standalone activity, but will joi...

whitepaper

Catalysis is an essential part of many pharmaceutical processes. With increasing innovation in catalytic chemistry coupled with ever increasing regulatory requirements for residual levels of metal catalysts, particularly Platinum and Palladium, the r...

whitepaper

Process measuring instruments are essential tools for monitoring and controlling critical process parameters. Risk analysis identifies critical process parameters which must be monitored and controlled during the production process in order to achiev...

whitepaper

That is the provocative question I have been posing to pharmaceutical marketers, industry leaders and stakeholders over the last few months. This supplement brings together a series of articles, insights and discussions Kantar Health has produced in ...

whitepaper

Featuring the views and experiences of industry experts from inside and outside of pharma & healthcare, this series of four white papers from PharmiWeb Solutions looks at how pharma can make the right decisions about the technologies, devices and ski...

whitepaper

A solution to the current funding crisis for budget-busting breakthrough treatments has been proposed by Soeren Mattke, senior scientist at the RAND Corporation think tank, involving payers and governments borrowing from pharma. However, multiple obs...

whitepaper

Ranked as the 16th largest pharmaceutical market in the world and the seventh biggest in Europe in 2011 in terms of sales, Turkey's domestic market offers many opportunities. According to data from the Association of Research-Based Pharmaceutical Com...

whitepaper

The development of a new drug is a complex venture associated with in-depth analysis and difficult decisions prior to commercialization of the product. A lot of drug sponsors find themselves lacking experience, equipment, or both in development of th...

whitepaper

As demographics change, and more and more new pharmaceutical and medical devices come to market, content plays an increasingly important role in regulatory requirements, and physician and patient knowledge and support. Yet content is still created an...

whitepaper

Origin’s ethos is everything we do, we innovate. Whether that is a new child resistant closure for a major pharmaceutical company, to a new, state of the art Enterprise Resource Planning System to further improve the customer’s experience with Origin...

whitepaper

Glass has many advantages over other packaging materials used for pharmaceutical primary packaging. It has only a few components, ensuring reliable information on the chemical resistance and protection of the medicines. In this manner, reliable recom...

whitepaper

Aptar Pharma recently hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and ex...

whitepaper

Silicones are used in pharmaceutical applications as part of formulations, as well as during manufacturing and in packaging. The term ‘silicones’ encompasses a large number of compounds based on polydialkylsiloxanes. The most common are trimethylsily...

whitepaper

Pharmadule, the world leader in modular manufacturing facilities for the pharmaceutical industry, has in recent years been working with Munters to supply humidity controlled facilities for Eli Lilly Indianapolis, Baxter Bloomington USA and Eli Lilly ...

whitepaper

As any senior executive within an organisation knows, the reduction of waste and, more importantly, the cost associated with that waste can have a major effect on any business. Whilst some waste is unavoidable, an executive can begin to implement pri...

whitepaper

To date / the Indian pharma market has been dominated by the trade/retail segment which has contributed up to 85% of the market value. This is unlike most mature markets globally which usually operate in a multi-channeled business model involving not...

whitepaper

In recent years, pharmaceutical and biotechnology companies have come to understand that supply chains ultimately impact the delivery of healthcare, and supply chains can and should serve as value centers for their company and the end-user. While the...

whitepaper

Porton Biopharma Limited (PBL) is a UK-based company experienced in developing, manufacturing and bringing life-saving biopharmaceutical therapeutics and vaccines to market. The company is expert at taking concepts from the research laboratory, progr...

whitepaper

As pharma companies expand, they are looking more and more to biologics for their next potential blockbusters. However, this class of product ranging from well-established large molecule drugs to truly novel therapies poses major challenges because o...

whitepaper

Conducti ng clinical trials for rare, debilitate ng diseases can be particularly challenging, owing to the smaller patient population with limited mobility and greater caregiving requirements. Direct-to-patient shipping of clinical trial drugs, while...